Phreesia, Inc. (NYSE:PHR) SVP Sells $22,539.00 in Stock

by · The Cerbat Gem

Phreesia, Inc. (NYSE:PHR – Get Free Report) SVP David Linetsky sold 1,100 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $20.49, for a total value of $22,539.00. Following the completion of the sale, the senior vice president now directly owns 200,207 shares of the company’s stock, valued at approximately $4,102,241.43. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

David Linetsky also recently made the following trade(s):

  • On Tuesday, October 15th, David Linetsky sold 2,011 shares of Phreesia stock. The shares were sold at an average price of $21.03, for a total value of $42,291.33.
  • On Thursday, September 19th, David Linetsky sold 24 shares of Phreesia stock. The shares were sold at an average price of $24.04, for a total transaction of $576.96.
  • On Tuesday, September 17th, David Linetsky sold 36 shares of Phreesia stock. The shares were sold at an average price of $24.77, for a total value of $891.72.
  • On Tuesday, September 10th, David Linetsky sold 1,716 shares of Phreesia stock. The shares were sold at an average price of $23.25, for a total value of $39,897.00.

Phreesia Price Performance

NYSE:PHR traded down $0.01 during trading hours on Tuesday, reaching $19.60. 317,270 shares of the company traded hands, compared to its average volume of 450,629. Phreesia, Inc. has a 1-year low of $12.05 and a 1-year high of $29.16. The stock has a market cap of $1.13 billion, a P/E ratio of -10.89 and a beta of 0.93. The firm’s 50-day moving average is $23.16 and its 200-day moving average is $22.38. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.77 and a quick ratio of 1.77.

Phreesia (NYSE:PHR – Get Free Report) last posted its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. The firm had revenue of $102.12 million during the quarter, compared to analysts’ expectations of $101.76 million. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. Equities research analysts expect that Phreesia, Inc. will post -1.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Phreesia

A number of institutional investors have recently modified their holdings of PHR. Vanguard Group Inc. boosted its position in Phreesia by 4.4% during the fourth quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock worth $107,148,000 after acquiring an additional 194,035 shares during the last quarter. WoodTrust Financial Corp lifted its stake in shares of Phreesia by 87.9% during the 1st quarter. WoodTrust Financial Corp now owns 31,000 shares of the company’s stock worth $742,000 after purchasing an additional 14,500 shares during the period. Diversified Trust Co acquired a new stake in shares of Phreesia during the first quarter worth $256,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Phreesia by 31.7% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 132,581 shares of the company’s stock valued at $3,173,000 after purchasing an additional 31,925 shares during the period. Finally, Essex Investment Management Co. LLC increased its stake in Phreesia by 1.9% in the first quarter. Essex Investment Management Co. LLC now owns 59,764 shares of the company’s stock valued at $1,430,000 after purchasing an additional 1,102 shares during the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Thursday, September 5th. Truist Financial upped their price objective on Phreesia from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, September 6th. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research note on Thursday, September 5th. JPMorgan Chase & Co. boosted their price objective on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, September 9th. Finally, Robert W. Baird lifted their price target on shares of Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.42.

View Our Latest Analysis on Phreesia

About Phreesia

(Get Free Report)

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

Read More